Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CVS GroupCVSGF 90 Peter Lynch Fair Value is $12.23 as of Jul. 16, 2026, which is 871% above its 10-year median of 1.26. GuruFocus rates CVSGF with a GF Score™ of 90/100 and a GF Value™ of $16.38 (Fairly Valued). The stock has 5 warning signs investors should review. Among 169 Healthcare Providers & Services companies, CVS Group ranks worse than 60.36% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, CVS Group's PEG is 1. CVS Group's 5-Year TTM EBITDA Growth Rate is 11.25.
CVS Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $1.09. Therefore, the Peter Lynch Fair Value for today is $12.23.
As of today (2026-07-16), CVS Group's share price is $15.65. CVS Group's Peter Lynch fair value is $12.23. Therefore, CVS Group's Price to Peter Lynch Fair Value Ratio for today is 1.28.
The historical rank and industry rank for CVS Group's Peter Lynch Fair Value or its related term are showing as below:
CVSGF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67 Med: 1.26 Max: 1.82
Current: 1.49
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of CVS Group was 1.82. The lowest was 0.67. And the median was 1.26.
CVSGF's Price-to-Peter-Lynch-Fair-Value is ranked worse than 60.36% of 169
companies
in the Healthcare Providers & Services industry
Industry Median: 1.15
vs CVSGF: 1.49
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
CVS Group (OTCPK:CVSGF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 11.25 instead of 15 in this case.
CVS Group's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
15.65
/
12.23
=
1.28
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Group Peter Lynch Fair Value Related Terms
CVS Group Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for CVS Group's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVSGF vs HCA, THC, DVA: Peter Lynch Fair Value Comparison
For the Medical Care Facilities subindustry, CVS Group's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Group Price-to-Peter-Lynch-Fair-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CVS Group's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where CVS Group's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CVS Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $1.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $12.23 mean?
CVS Group (CVSGF) has a Peter Lynch Fair Value of $12.23 as of Jul. 16, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CVS Group and its competitors. This is 871% above median its historical median of 1.26. Over the past decade, CVS Group's Peter Lynch Fair Value has ranged from 0.67 to 1.82. According to the industry distribution chart, CVS Group ranks #102 out of 169 companies in the Healthcare Providers & Services industry, placing it in the top 60.4%.
Is CVS Group's Peter Lynch Fair Value too high?
CVS Group's current Peter Lynch Fair Value of $12.23 is 871% above median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 1.82. The Healthcare Providers & Services industry median Peter Lynch Fair Value is 1.15. CVS Group's value of $12.23 is 963.5% above this industry median. Based on the distribution chart, CVS Group ranks #102 out of 169 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, CVS Group has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CVS Group's Peter Lynch Fair Value compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CVS Group ranks #102 out of 169 companies for Peter Lynch Fair Value. This places CVS Group in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.15. CVS Group's value of $12.23 is 963.5% above this benchmark. Historically, CVS Group's own Peter Lynch Fair Value has ranged from 0.67 to 1.82 over the past decade. While the company's 10-year median is 1.26 vs. the industry median of 1.15, CVS Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Healthcare Providers & Services company?
The median Peter Lynch Fair Value among Healthcare Providers & Services companies is 1.15, based on 169 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CVS Group's current Peter Lynch Fair Value of $12.23 is 963.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CVS Group and its competitors. For the Healthcare Providers & Services industry, the median Peter Lynch Fair Value is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CVS Group's current Peter Lynch Fair Value is $12.23, which is 871% above median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Group stock overvalued right now?
Based on GuruFocus' analysis, CVS Group (CVSGF) is currently considered Fairly Valued. The stock's GF Value™ is $16.38, compared to a current price of $15.65 — trading 4.5% below its estimated fair value. The current Peter Lynch Fair Value is $12.23, which is 871% above median its 10-year median of 1.26 and 963.5% above the Healthcare Providers & Services industry median of 1.15. CVS Group's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For CVS Group (CVSGF), the current Peter Lynch Fair Value is $12.23 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Group (CVSGF) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Group stock appears to be undervalued.
The current stock price of $15.65 is trading 4.5% below its estimated GF Value™ of $16.38.
GuruFocus considers CVS Group to be Fairly Valued.
Key valuation signals for CVSGF:
Peter Lynch Fair Value: $12.23 (871% above median its 10-year median of 1.26)
GF Value™: $16.38 vs. price of $15.65 (4.5% below fair value)
Industry Position: 963.5% above the Healthcare Providers & Services median (#102 of 169)
No single metric tells the full story. See the CVSGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Group PLC is a veterinary service provider in the United Kingdom. The group operates through three business divisions: Veterinary Practices, Laboratories, Crematoria, and Online Retail Business. The veterinary practice segment generates the majority of the revenues. The company facilitates its veterinary services through its diagnostics, laboratory reports, and pet cremation services. It also offers retail pharmacy through Animed Direct. Geographically, it generates the majority of its revenue from the United Kingdom and also operates in Australia.
90GF Score
Get the complete analysis for CVSGF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSGF has been successfully added to your 
